Research Assistant Professor

 

Education/Training

Undergraduate: Lucknow University
Graduate: Central Drug Research Institute
Post-Doctoral Fellowship: Fukuoka University
Post-Doctoral Fellowship: Medical College of Wisconsin

 

Areas of Interest and Expertise

Targeted immunotherapy against pediatric B-cell lymphoma/leukemia

 

Publications

Awasthi A, Ayello J, Van de ven C,  Elmacken M, ,  Sabulski A,  Barth M, Czuczman MS , Islam, H, Klein C, and Cairo MS. (2015)  Obinutuzumab (GA101) compared to rituximab significantly enhances cell death, antibody dependent cytotoxicity (ADCC) and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): Potential targeted therapy in patients with poor risk CD20+BL and pre-B-ALL. Br J Haematol.171 (5):763-75.

 

Malarkannan S, Awasthi A, Kamalakannan R, Kumar P, Schuldt KM, Bartoszek A, Manoharan A, Goldner NK, Umhoefer KM and Thakar MS. IQGAP1 (2012) : A Regulator of Intracellular Spacetime Relativity. J of Immunology, 188 (5).

 

Awasthi A, Samarakoon A, Chu H, Kamalakannan, R, Quilliam LA, White GC 2nd, Chrzanowska-Wodnicka M, , Malarkannan S.(2010) Rap1b facilitates NK cell functions via IQGAP1-mediated signalosomes. J Exp Med, 30; 207(9):1923-38.

 

Awasthi A, Samarakoon A, Dai X, Wen R, Wang D, Malarkannan S.(2008) Deletion of PI3K-p85alpha gene impairs lineage commitment, terminal maturation, cytokine generation and cytotoxicity of NK cells. Genes and Immunity, 9(6):522-35.

 

Chu H, Awasthi A, White GC 2nd, Chrzanowska-Wodnicka M, Malarkannan S (2008).Rap1b regulates B cell development, homing, and T cell-dependent humoral immunity. J Immunology, 181(5):3373-3383.

 

Bhatnagar PK, Awasthi A, Nomellini JF, Smit J, Suresh MR.(2006) Anti-tumor effects of the bacterium Caulobacter crescentus in murine tumor models. Cancer Biol Ther, 5(5):485-91.

 

Awasthi A, Matsunaga Y, Yamada T. (2005) Amyloid-beta causes apoptosis of neuronal cells via caspase cascade, which can be prevented by amyloid-beta-derived short peptides. Exp Neurol, 196(2):282-9.

 

Tripathi R, Awasthi A, Dutta GP. (2005) Mefloquine resistance reversal action of ketoconazole-A cytochrome P450 inhibitor, against mefloquine-resistant malaria. Parasitology, 130(Pt 5):475-9.

 

Awasthi A, Dutta GP, Bhakuni V and Tripathi R.(2004) Resistance reversal action of ketoconazole against mefloquine resistance of Plasmodium yoelii nigeriensis. Exp Parasitol, 107(3-4):115-9.

 

Matsunaga Y, Fujii A, Awasthi A, Yokotani J, Takakura T, Yamada T.(2004) Eight-residue A-beta peptides inhibit the aggregation and enzymatic activity of Abeta42. Regul Pept, 2004, 15; 120(1-3):227-36.

 

Awasthi A, Kumar A, Upadhyay S N, Yamada T and Matsunaga Y. (2003) Nitric oxide protects against chloroquine resistant Plasmodium yoelli nigerensis parasites in vitro. Exp Parasit, 105(3-4):184-91.

 

Matsumoto H, Liao S, Arakawa F, Ueno A, Abe H, Awasthi A, Kuroki M, Kuroki M.(2002) Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody. Anticancer Res, 22(4):2001-7.

 

Abe H, Kuroki M, Tachibana K, Li T, Awasthi A, Ueno A, Matsumoto H, Imakiire T, Yamauchi Y, Yamada H and Kuroki M. (2002) Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen. Anticancer Res, 22(3):1575-80.

 

Dutta GP, Puri SK, Awasthi A, Mishra M, Tripathi R.(2000) Pyronaridine: an effective antimalarial against multidrug-resistant malaria. Life Sci; 67(7):759-63.

 

Dhawan S, Awasthi A, Tripathi R, Puri S K and Dutta G P.(2000) Reversal of chloroquine/ mefloquine resistance of Plasmodium yoelli nigeriensis (MDR) by IFN-g and chloroquine resistance by Poly IC:LC. Journal of Parasitic Diseases, 24:195-201.

 

Awasthi A, Mehrotra S, Bhakuni V, Dutta GP, Levy HB and Maheshwari RK(1997). Poly ICLC enhances the antimalarial activity of chloroquine against multidrug-resistant Plasmodium yoelli nigeriensis in mice. J Interferon Cytokine Res. 17 (7):419-23.